50551-57-0

Basic information

• Product Name: ethyl 6-methoxybenzofuran-2-carboxylate
• Synonyms: ethyl 6-methoxybenzofuran-2-carboxylate;2-Benzofurancarboxylic acid, 6-Methoxy-, ethyl ester;ethyl 6-Methoxy-1-benzofuran-2-carboxylate;ETHYL 6-METHOXYBENZOFURAN-2-CARBOXYLATE(WXC06043)
• CAS NO: 50551-57-0
• Molecular Formula: C12H12O4
• Molecular Weight: 220
• Mol File: 50551-57-0.mol
• Article Data: 16

Chemical Properties

• Melting Point: 87 °C
• Boiling Point: 316.2±22.0 °C(Predicted)
• Appearance: /
• Density: 1.192±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: ethyl 6-methoxybenzofuran-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 6-methoxybenzofuran-2-carboxylate(50551-57-0)
• EPA Substance Registry System: ethyl 6-methoxybenzofuran-2-carboxylate(50551-57-0)

Safety Data

• Hazardous Substances Data: 50551-57-0(Hazardous Substances Data)

Upstream product

• 150-19-6 O-methylresorcine 
• 4504-12-5 ethyl 5-oxo-2-phenyl-2,5-dihydroisoxazole-4-carboxaldehyde 
• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 105-36-2 ethyl bromoacetate 
• 105-39-5 chloroacetic acid ethyl ester 
• 685-87-0 Diethyl 2-bromomalonate 
• 76322-06-0 2-ethoxycarbonylmethoxy-4-methoxybenzaldehyde 

Downstream Products

• 50551-61-6 6-methoxybenzofuran-2-carboxylic acid 
• 1462470-08-1 (E)-6-(2-(3-oxazolidinyl)ethoxy)-2-(4-dimethylaminostyryl)benzofuran hydrochloride 
• 1089681-69-5 (E)-4-(2-(6-methoxybenzofuran-2-yl)vinyl)-N-methylaniline 
• 1089682-48-3 (E)-tert-butyl (4-(2-(6-methoxybenzofuran-2-yl)vinyl)phenyl)(methyl)carbamate 
• 1462470-44-5 (E)-6-(methoxy)-2-(4,4′-methyl(2-fluoroethyl)aminostyryl)benzofuran 
• 1462469-84-6 (E)-6-(2-(3-oxazolidinyl)ethoxy)-2-(4-dimethylaminostyryl)benzofuran 
• 1089681-44-6 (E)-6-hydroxy 2-(4-dimethylaminostyryl)benzofuran 
• 1089681-42-4 (E)-6-methoxy 2-(4-dimethylaminostyryl)benzofuran 
• 1462470-22-9 ((6-methoxybenzofuran-2-yl)methyl)triphenylphosphonium bromide 
• 1254572-50-3 C₁₉H₁₈N₂O₂ 
• 53860-74-5 6-methoxy-1-benzofuran-2-carbaldehyde 
• 41910-91-2 2,3-dihydro-2-carboxy-6-methoxybenzofuran 

Relevant articles and documents

Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site

A novel series of shikonin-benzo[b]furan derivatives were designed and synthesized as tubulin polymerization inhibitors, and their biological activities were evaluated. Most compounds revealed the comparable anti-proliferation activities against the cancer cell lines to that of shikonin and simultaneously low cytotoxicity to non-cancer cells. Among them, compound 6c displayed powerful anti-cancer activity with the IC50 value of 0.18 μM against HT29 cells, which was significantly better than that of the reference drugs shikonin and CA-4. What's more, 6c could inhibit tubulin polymerization and compete with [3H] colchicine in binding to tubulin. Further biological studies depicted that 6c can induce cell apoptosis and cell mitochondria depolarize, regulate the expression of apoptosis related proteins in HT29 cells. Besides, 6c actuated the HT29 cell cycle arrest at G2/M phase, and influenced the expression of the cell-cycle related protein. Moreover, 6c displayed potent inhibition on cell migration and tube formation that contributes to the antiangiogenesis. These results prompt us to consider 6c as a potential tubulin polymerization inhibitor and is worthy for further study.

Efficient synthesis of chiral benzofuryl β-amino alcohols via a catalytic asymmetric Henry reaction

Chiral β-amino alcohol ligands were found effective for the copper(ii)-catalyzed asymmetric Henry reaction of benzofuran-2-carbaldehydes with nitromethane, which led to the formation of (S)-enriched benzofuryl β-nitro alcohols with satisfactory enantioselectivities (up to 98% ee). Using this catalytic protocol, bioactive (S)-benzofuryl β-amino alcohols could be conveniently prepared in short steps.

Benzocarbazoles five-membered unsaturated heterocyclic compound or its pharmaceutically acceptable salts and its preparation method, pharmaceutical composition and its application

Provided in the present invention are an unsaturated 5-membered benzo-heterocyclic compound with the structure as shown in general formula I or pharmaceutical salts thereof, and a preparation method, a pharmaceutical composition and the use thereof. Experiments have shown that the compound of the present invention has the effects of upregulating the expression activity of bone morphogenetic protein BMP-2 and anti-osteoporosis in vivo, and also has the effect of improving SAMP6 mice osteoporosis symptoms. Activity tests in vitro have shown that the compound of the present invention shows an obvious upregulation effect on bone morphogenetic protein BMP-2.